Photo detail

“Our investors have articulated that what will transform the potential of Halozyme is success in pancreas cancer,” CEO Helen Torley told the San Diego Business Journal in March.

Stories this photo appears in:

Halozyme Expects Key Data On Cancer Drug

2019 Look Ahead: Health Care

San Diego’s Halozyme is headed for an inflection point. In the second half of the year, analysts expect key clinical trial data to be released on Halozyme’s pegph20 in metastatic pancreas cancer. The therapeutic candidate is in a late-stage trial, or known as phase 3.

Tease photo